ZB

Zura Bio Limited

ZURA·NASDAQ

$4.10

-5.9%
HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$266.59M
EPS-1.0600
P/E Ratio-4.97
Earnings Date08/13/2026

zura

Cost of Revenue

Last Annual Value

49.00K

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

ZB

Zura Bio Limited Competitors Analysis of Cost of Revenue

ZURA · NASDAQ
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
49.00K
N/AN/AN/A 
2.39M
N/AN/AN/A
3.65M
1.1%29.9%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
4.10M
N/AN/AN/A
36.00K
N/AN/AN/A
698.89K
N/A-9.5%N/A
8.44M
-1.0%16.0%N/A
0.00
N/AN/AN/A
129.00K
-86.2%N/A4.9%
ZB

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.1, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

Intrinsic Value
Current Price: $4.1